Better brain zaps: new study tests precision targeting for depression treatment
NCT ID NCT03851380
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This study tests whether using MRI to guide transcranial magnetic stimulation (TMS) works better than the usual scalp-based method for treating depression. It involves 54 participants, including those with treatment-resistant depression and others with COVID-related distress. The goal is to improve targeting accuracy and measure changes in quality of life and functioning.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Transcranial magnetic stimulation (TMS) and transcranial electrical stimulation (tES)
- What this could lead to
- If successful, this could make TMS therapy more effective for depression by improving how doctors target the right brain areas.
- What could go wrong
- This is a small, early-stage study focused on targeting accuracy, not a large trial testing a new treatment. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
54 people
The number who actually took part.
- Started
-
Sep 2019
- Finished
-
Jul 2024
- Lead sponsor
-
A government agency
The lead sponsor is a US federal agency other than the NIH.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Veteran patients with depression or COVID-19-related distress
- Ages
-
18 to 89 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Cohort 1: Capacity and willingness to participant in TMS, and fMRI as well as satisfying criteria for diagnosis. * Between 18 and 89 years of age. * Ability to obtain a Motor Threshold (MT) with single pulse TMS * Ability to safely and comfortably undergo an MRI and TMS * Able to read, verbalize, understand and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments * Depression (PHQ-9 \>= 10 and functional impairment present indicated with "difficulty" question OR sufficiently depressed to be enrolled in rTMS therapy) * Confirmed diagnosis of Major Depressive Disorder (MDD) * Can maintain all existing treatments (e.g. psychopharmacology, psychotherapy, etc.,) throughout course of the three sessions (psychological / functional assessments, MRI, and TMS), with modifications only as needed for clinical management * Is a Veteran Cohort 2: * Between 18 and 89 years of age * Ability to safely and comfortably undergo an MRI and tES * Ability to read, verbalize, understand, and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments * Depression (PHQ-9 \>= 10) and endorse that the COVID-19 pandemic has worsened their depression OR have a score on the COVID Stress Scale (CSS) on any item of 3 or greater indicating stressor is "very" or "often" a problem will allow the Veteran to enter the study Exclusion Criteria: * Participants who can not safely and comfortably undergo MRI OR TMS (or TES for Cohort 2) * If their language is not primarily English they may be excluded depending on how dependent the imaging and cognitive tasks are on language * Additionally, participants may be excluded if they do not fully understand the consenting process and cannot communicate sufficiently in English to participate in the therapy (d/t language barrier, etc.) * An example of safety screen details for an MRI is detailed in the Stanford University MRI screening form * MRI exclusions include having any non-removable device or implant that makes scanning unsafe, claustrophobia, and size (e.g. weight, girth) beyond the constraints of the MRI and scanner bed * For TMS the investigators will follow safety guidelines set by Rossi et. al.,2009 * Specifically, the investigators will not include subjects whose Motor Threshold (MT) is greater than 84% of maximum device output because mathematically they would not be able to be safely stimulated using the standard 120% of MT (i.e. the device cannot stimulate more than 100% of its potential output) * The investigators will report these high MT data in our secondary analyses. Additional TMS exclusions include any history or condition that puts patients at risk for a seizure * Pregnant or planning to become pregnant within the next 3 months * Lifetime history of moderate or severe traumatic brain injury, current unstable medical conditions, current (or past if appropriate) significant neurological disorder, or lifetime history of: * seizure disorder * primary or secondary CNS tumors * stroke * cerebral aneurysm * Significant cognitive impairment (Montreal Cognitive Assessment \[MoCA\] \< 16) * Comorbidities (e.g. PTSD) determined not to be the primary diagnosis * Have a lifetime diagnosis of schizophrenia, schizoaffective disorder, schizophreniform, delusional disorder, or current psychotic symptoms * Have a diagnosis of obsessive-compulsive disorder assessed by a study investigator to be causing greater impairment than MDD * Have active suicidal intent or plan in which case Dr. Rosen will determine whether the patient needs to be referred for hospitalization * Presence of any other condition or circumstance that, in opinion of the investigator team, has the potential to prevent study completion and/or to have a confounding effect on outcome assessments Exclusion Criteria for Cohort 2: * Participants who cannot safely and comfortably undergo MRI or TES * Pregnant or lactating female or planning to become pregnant within the next 3 months * Lifetime history of moderate or severe traumatic brain injury or tumor * Significant cognitive impairment (Montreal Cognitive Assessment \[MoCA\] \< 16 OR equivalent score on \[MoCA-BLIND\] and judgement of a clinician that the test is validly reflecting a significant disabling cognitive impairment * Have a lifetime diagnosis of: * schizophrenia * schizoaffective disorder * schizophreniform * delusional disorder * or current psychotic symptoms * Have a diagnosis of obsessive-compulsive disorder or unstable substance use disorder * Presence of actively infections/contagious disease such as the flu or SARS-CoV-2
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID stress are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VA Palo Alto Health Care System, Palo Alto, CA
Palo Alto, California, 94304-1207, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Can a phone app that blocks distracting apps ease depression?
- Can teachers and a phone app ease teen depression?
- Can imagining exercise boost brain power after spinal cord injury?
- Can an antipsychotic restore feelings in people with depression?
- Can a group program teach teens to cope before therapy starts?